ACS chemical neuroscience molecule spotlight on Fanapt.
The new mixed dopamaine D(2)/serotonin 5-HT(2A) antagonist, Fanapt (iloperidone), was approved by the FDA on May 6th, 2009 for the treatment of schizophrenia in adults.
Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology and Vanderbilt Program in Drug Discovery, Nashville, Tennessee, USA.
Corey R
CR
Hopkins
D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D018795:Device Approval; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D012559:Schizophrenia / Q000188:drug therapy; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D007555:Isoxazoles; D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D058830:Serotonin 5-HT2 Receptor Antagonists; C081732:iloperidone